Interim Report April - September 2023
Growth despite large impact from the global antibiotics shortage, several important MA approvals and expansion of pipelineJuly - September 2023 · Consolidated sales during the second quarter, July to September amounted to SEK 59.6 (73.3) million. Adjusted for non-recurring sales the revenue amounted to 59.6 (51.2) MSEK, an increase of 16%. · Gross profit amounted to SEK 23.9 (28.6) million for the quarter, a decrease of 16%. · EBIT amounted to SEK 6.6 (11.9) million, a decrease of 45%. The operating margin was 11% (16%). · EBITDA margin was 14%. · Earnings per share before